عنوان
پدید آورنده
موضوع
رده
RC643 .C493 2007eb
RC643
.
C493
2007eb
کتابخانه
محل استقرار
INTERNATIONAL STANDARD BOOK NUMBER
(Number (ISBN
0849379563
(Number (ISBN
1280866616
(Number (ISBN
9780849379567
(Number (ISBN
9781280866616
Erroneous ISBN
0849379555
Erroneous ISBN
9780849379550
NATIONAL BIBLIOGRAPHY NUMBER
Number
b746528
TITLE AND STATEMENT OF RESPONSIBILITY
Title Proper
Chronic myeloid leukemia /
General Material Designation
[Book]
First Statement of Responsibility
edited by Jorge Cortes, Michael Deininger.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
New York, NY :
Name of Publisher, Distributor, etc.
Informa Healthcare,
Date of Publication, Distribution, etc.
©2007.
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource (viii, 161 pages) :
Other Physical Details
color illustrations
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index.
CONTENTS NOTE
Text of Note
1. BCR-ABL as a molecular target / Michael Deininger -- 2. Allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia / Mukta Arora and Mary M. Horowitz -- 3. Where Are We Today with Imatinib Therapy? / John M. Goldman -- 4. Monitoring chronic myeloid leukemia in 2006 / Nicola Hurst, Timothy P. Hughes, and Susan Branford -- 5. Dasatinib : a dual ABL and SRC inhibitor / Alfonso Quintás-Cardama, Hagop Kantarjian, and Jorge Cortes -- 6. Nilotinib (AMN107) for the treatment of chronic myelogenous leukemia / Elias Jabbour [and others] -- 7. Resistance to imatinib / Justus Duyster and Nikolas von Bubnoff -- 8. Immunotherapy of chronic myeloid leukemia / Monica Bocchia and Francesco Lauria -- 9. Molecular targets other than Bcr-Abl : how to incorporate them into the CML therapy? / Junia V. Melo and David J. Barnes -- 10. Blastic transformation of chronic myelogenous leukemia : does BCR-ABL orchestrate disease progression? / Bruno Calabretta and Danilo Perrotti -- 11. Early intensification of therapy : the role of high-dose imatinib and imatinib-based combinations / François Guilhot [and others].
0
SUMMARY OR ABSTRACT
Text of Note
Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve p.
ACQUISITION INFORMATION NOTE
Source for Acquisition/Subscription Address
Ingram Content Group
Stock Number
TANDF_160251
OTHER EDITION IN ANOTHER MEDIUM
Title
Chronic myeloid leukemia.
International Standard Book Number
0849379555
TOPICAL NAME USED AS SUBJECT
Chronic myeloid leukemia.
Antineoplastic Agents-- therapeutic use.
Fusion Proteins, bcr-abl-- antagonists & inhibitors.
Hematopoietic Stem Cell Transplantation.
Immunotherapy-- methods.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive-- therapy.
Protein Kinase Inhibitors-- therapeutic use.
Chronic myeloid leukemia.
PHILOSOPHY-- Logic.
(SUBJECT CATEGORY (Provisional
MJCL
PHI-- 011000
DEWEY DECIMAL CLASSIFICATION
Number
16
.
99/41906
Edition
22
LIBRARY OF CONGRESS CLASSIFICATION
Class number
RC643
Book number
.
C493
2007eb
OTHER CLASS NUMBERS
Class number
2007
C-396
Class number
WH
250
Book Number
C55695
2007
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Cortés F., Jorge E., (Jorge Eduardo Cortés Franco)
Deininger, Michael.
ORIGINATING SOURCE
Date of Transaction
20201204064043.0
Cataloguing Rules (Descriptive Conventions))
pn
ELECTRONIC LOCATION AND ACCESS
Electronic name
مطالعه متن کتاب [Book]
Y
